Circulation:视网膜血管管径可预测心血管预后

2016-10-30 MedSci MedSci原创

背景:视网膜小动脉狭窄和视网膜静脉增快与不良心血管预后相关。研究者旨在调查视网膜血管口径与心血管预后的相关性,并且根据2013年美国心脏病/美国心脏协会汇集队列方程(PCE)提供增量值预测动脉粥样硬化性心血管疾病事件(ASCVE)的发生。方法: 在社区动脉粥样硬化风险研究(ARIC)中,无ASCVE或心力衰竭(HF)史的男性和女性共10470,这些受试者行视网膜摄影(1993-1995年)。结果:

背景:视网膜小动脉狭窄和视网膜静脉增快与不良心血管预后相关。研究者旨在调查视网膜血管口径与心血管预后的相关性,并且根据2013年美国心脏病/美国心脏协会汇集队列方程(PCE)提供增量值预测动脉粥样硬化性心血管疾病事件(ASCVE)的发生。

方法:在社区动脉粥样硬化风险研究(ARIC)中,无ASCVE或心力衰竭(HF)史的男性和女性共10470,这些受试者行视网膜摄影(1993-1995年)。

结果:随访平均的时间为16年,共发生1779例冠心病事件,548例发生缺血性卒中,1395例心衰事件,2793例死亡。在那些视网膜静脉增宽,视网膜小动脉狭窄的患者,所有预后的发生率较高。校正PCE风险评分的变量,

视网膜小静脉增宽[每增加一个SD,HR:1.13(95%CI:1.08-1.18),HR 1.18(1.07-1.31)和HR 1.10(1.00-1.20)]和视网膜小动脉狭窄[每下降SD, 1.06(1.01-1.11),HR 1.14(1.03-1.26)和HR 1.13(1.03-1.24)]与男性和女性有较高的卒中和死亡的风险相关,而与女性冠心病事件发生相关,与男性冠心病事件发生不相关。校正收缩压后,视网膜血管管径与HF无显著性关系。PCE-预测10年ASCVE风险<5%(总体风险为3.9%),与动脉管径最宽者相比,动脉管径最狭窄者10年事件发生率分别为2.8%,5.6%(宽VS 窄静脉:5% vs. 5.6%)。视网膜血管口径为21%的低风险的妇女(11%的女性)为中等风险(> 5%)。

结论:视网膜小动脉狭窄和视网膜静脉增宽与男性和女性长期死亡风险及缺血性卒中风险相关,而仅女性冠心病相关。这些检查作为一种便宜、可再生的生物标志物为低风险的妇女预测ASCVE风险增加当前指南的增量值。

原始出处:

Seidelmann SB, Claggett B,et al. Retinal Vessel Calibers in Predicting Long-term Cardiovascular Outcomes: The Atherosclerosis Risk in Communities Study. Circulation. 2016 Sep 28.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=154809, encodeId=b522154809d9, content=做OCT看视网脱A多烦, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff901728138, createdName=1dedfe95m66(暂无匿称), createdTime=Thu Nov 10 15:23:01 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269841, encodeId=3d111269841e8, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Nov 01 13:35:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508627, encodeId=5901150862e8c, content=<a href='/topic/show?id=884c51916cd' target=_blank style='color:#2F92EE;'>#心血管预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51916, encryptionId=884c51916cd, topicName=心血管预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de8d9990502, createdName=xiaogang320, createdTime=Tue Nov 01 13:35:00 CST 2016, time=2016-11-01, status=1, ipAttribution=)]
    2016-11-10 1dedfe95m66(暂无匿称)

    做OCT看视网脱A多烦

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=154809, encodeId=b522154809d9, content=做OCT看视网脱A多烦, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff901728138, createdName=1dedfe95m66(暂无匿称), createdTime=Thu Nov 10 15:23:01 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269841, encodeId=3d111269841e8, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Nov 01 13:35:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508627, encodeId=5901150862e8c, content=<a href='/topic/show?id=884c51916cd' target=_blank style='color:#2F92EE;'>#心血管预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51916, encryptionId=884c51916cd, topicName=心血管预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de8d9990502, createdName=xiaogang320, createdTime=Tue Nov 01 13:35:00 CST 2016, time=2016-11-01, status=1, ipAttribution=)]
    2016-11-01 zutt
  3. [GetPortalCommentsPageByObjectIdResponse(id=154809, encodeId=b522154809d9, content=做OCT看视网脱A多烦, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ff901728138, createdName=1dedfe95m66(暂无匿称), createdTime=Thu Nov 10 15:23:01 CST 2016, time=2016-11-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1269841, encodeId=3d111269841e8, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Tue Nov 01 13:35:00 CST 2016, time=2016-11-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1508627, encodeId=5901150862e8c, content=<a href='/topic/show?id=884c51916cd' target=_blank style='color:#2F92EE;'>#心血管预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51916, encryptionId=884c51916cd, topicName=心血管预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=de8d9990502, createdName=xiaogang320, createdTime=Tue Nov 01 13:35:00 CST 2016, time=2016-11-01, status=1, ipAttribution=)]

相关资讯

2016AAO临床指南:视网膜及眼动脉阻塞发布

2016年10月,美国眼科学会(AAO)发布了视网膜及眼动脉阻塞指南,指南主要内容包括视网膜及眼动脉阻塞的临床表现,危险因素,诊断以及质量和及随访等内容。全文获取:下载地址:指南下载(需要扣积分2分, 梅斯医学APP免积分下载)